AngioDynamics Q3 revenue beats estimates on Med Tech strength, raises outlook

AngioDynamics

02/04/2026 11:11

Overview

US medical device maker's fiscal Q3 revenue rose 8.9%, beating analyst expectations

Adjusted EPS loss for fiscal Q3 narrowed and beat analyst expectations

Company raised full-year guidance for net sales and adjusted EBITDA

Outlook

AngioDynamics raises FY 2026 net sales guidance to $313.5-$315.5 mln from $312-$314 mln

Company lifts FY 2026 adjusted EBITDA forecast to $10-$12 mln from $8-$10 mln

AngioDynamics expects FY 2026 cash flow may be slightly negative due to inventory build

Result Drivers

MED TECH GROWTH - Double-digit growth in Med Tech segment, led by Auryon, mechanical thrombectomy (AlphaVac and AngioVac), and NanoKnife platforms

TARIFFS AND COST INFLATION - Gross margin declined due to tariffs, inflation, and manufacturing transition costs, in line with expectations

OPERATING DISCIPLINE - Profitability supported by disciplined execution of operating initiatives

Company press release: ID:nBwbjKjCGa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$78.4 mln
$76.77 mln (3 Analysts)
Q3 Adjusted EPS
Beat
-$0.07
-$0.11 (3 Analysts)
Q3 Adjusted Net Income
Beat
-$3 mln
-$4.45 mln (3 Analysts)
Q3 Net Income
-$8.1 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for AngioDynamics Inc is $18.00, about 50.8% above its April 1 closing price of $11.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)